Because Rab1A overexpressing HCC cells are sensitive to rapamycin, Rab1A can be potentially used as a surrogate biomarker to guide personalized, mTORC1-targeted HCC therapy. This evidence concerns the gene RAB1A and hepatocellular carcinoma.